Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Individuals with chronic diseases that require constant medical support are particularly vulnerable during wartime and often remain so after the last shot has been fired. What consequences might the Russia–Ukraine war bring for rheumatology?
The findings of a new study suggest that the adipokine FABP4 promotes multiple pathological changes in rheumatoid arthritis and could represent a new therapeutic target.
New research shows that one of the two main isoforms of the human FOXP3 transcription factor is associated with inflammatory transcriptional regulation and autoimmunity.
New research shows that annexin A1 has a protective role in periprosthetic osteolysis and could offer a therapeutic approach to this common cause of arthroplasty failure.
Three new reports of results from two clinical trials of bimekizumab indicate that it is safe and efficacious for the long-term treatment of patients with ankylosing spondylitis or psoriatic arthritis.
A new study uncovers a protective role for epidermal S100A9 in psoriasis and psoriatic arthritis, and highlights this alarmin as a potential biomarker of disease progression.
New research attempts to explore the cause of plasmacytoid dendritic cell hyperactivation in systemic lupus erythematosus by focusing on genetic risk variation.
In patients with autoimmune rheumatic disease, methotrexate therapy has been associated with poor immune response to vaccines, including those intended to provide protection against COVID-19. Emerging evidence supports the practice of temporarily discontinuing this treatment in order to improve immunogenicity.
Although the multitude of pathways involved in the pathogenesis of systemic lupus erythematosus (SLE) seem to be interconnected, each predominates in only a fraction of patients. This complexity means that many agents tested in SLE clinical trials — now including iberdomide — produce only a small clinical benefit.
In this Review, the authors discuss age-related arthropathy and the similarities and differences between childhood loss of immune tolerance and adult development of immune-mediated arthritis, and develop three hypotheses describing age-related mechanisms that contribute to the onset of arthritis.
This Review summarizes our understanding of sex- and gender-related differences in psoriatic arthritis, with a focus on disease progression and outcomes, underlying mechanisms and response to therapies.
Assessing systemic sclerosis (SSc) disease activity is challenging, and improved outcome measures are needed. This Review describes clinical and biochemical outcome measures of distinct features of SSc, with an emphasis on the dermatological manifestations and interstitial lung disease, including insights into biomarkers gained from single-cell RNA sequencing.
The paradoxical increase in gout flare risk upon initiation of urate-lowering therapy presents challenges for the measurement and analysis of gout flares in clinical trials of urate-lowering therapy. In this Perspective, the authors highlight these issues and discuss potential solutions.
